Literature DB >> 21154521

Discounting and decision making in the economic evaluation of health-care technologies.

Karl Claxton1, Mike Paulden, Hugh Gravelle, Werner Brouwer, Anthony J Culyer.   

Abstract

Discounting costs and health benefits in cost-effectiveness analysis has been the subject of recent debate - some authors suggesting a common rate for both and others suggesting a lower rate for health. We show how these views turn on key judgments of fact and value: on whether the social objective is to maximise discounted health outcomes or the present consumption value of health; on whether the budget for health care is fixed; on the expected growth in the cost-effectiveness threshold; and on the expected growth in the consumption value of health. We demonstrate that if the budget for health care is fixed and decisions are based on incremental cost effectiveness ratios (ICERs), discounting costs and health gains at the same rate is correct only if the threshold remains constant. Expecting growth in the consumption value of health does not itself justify differential rates but implies a lower rate for both. However, whether one believes that the objective should be the maximisation of the present value of health or the present consumption value of health, adopting the social time preference rate for consumption as the discount rate for costs and health gains is valid only under strong and implausible assumptions about values and facts. 2010 John Wiley & Sons, Ltd.

Mesh:

Year:  2010        PMID: 21154521     DOI: 10.1002/hec.1612

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  61 in total

1.  Adding specialized clinics for remote-dwellers with chronic kidney disease: a cost-utility analysis.

Authors:  Natasha Wiebe; Scott W Klarenbach; Betty Chui; Bharati Ayyalasomayajula; Brenda R Hemmelgarn; Kailash Jindal; Braden Manns; Marcello Tonelli
Journal:  Clin J Am Soc Nephrol       Date:  2011-11-10       Impact factor: 8.237

2.  The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.

Authors:  Brad Spellberg; Priya Sharma; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

3.  Effect of discounting on estimation of benefits determined by hepatitis C treatment.

Authors:  Andrea Messori; Valeria Fadda; Dario Maratea; Sabrina Trippoli
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

4.  Perspective and desire in comparative effectiveness research: the relative unimportance of mere preferences, the central importance of context.

Authors:  Anthony J Culyer
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Exploring a new method for deriving the monetary value of a QALY.

Authors:  Carl Tilling; Marieke Krol; Arthur E Attema; Aki Tsuchiya; John Brazier; Job van Exel; Werner Brouwer
Journal:  Eur J Health Econ       Date:  2015-08-20

6.  Are some QALYs more equal than others?

Authors:  E J van de Wetering; N J A van Exel; J M Rose; R J Hoefman; W B F Brouwer
Journal:  Eur J Health Econ       Date:  2014-12-06

Review 7.  An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis.

Authors:  Matthew Franklin; James Lomas; Simon Walker; Tracey Young
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

8.  Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?

Authors:  Livio Garattini; Anna Padula
Journal:  J R Soc Med       Date:  2017-01-24       Impact factor: 5.344

9.  The Inclusion of Spillover Effects in Economic Evaluations: Not an Optional Extra.

Authors:  Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2019-04       Impact factor: 4.981

10.  When is it too expensive? Cost-effectiveness thresholds and health care decision-making.

Authors:  Werner Brouwer; Pieter van Baal; Job van Exel; Matthijs Versteegh
Journal:  Eur J Health Econ       Date:  2019-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.